Take Solutions Ltd
Founded in 2001 as a software services provider, TAKE is currently a technology driven, full service Clinical Research Organization. It helps biopharma companies throughout the drug development process, and beyond. Headquartered in Chennai, India, it has a global footprint spanning the Americas, Europe and the Asia Pacific region.
The co. delivers domain-intensive services in Life Sciences.
TAKE is the only full-service technology-driven Clinical Research Organization listed in India.
It has 1,70,000 regulatory submissions and submitted 5% of all regulatory submissions to USFDA 2012 to 2020.[1] [1] [2] [3]
- Market Cap ₹ 268 Cr.
- Current Price ₹ 18.1
- High / Low ₹ 29.6 / 12.7
- Stock P/E
- Book Value ₹ 7.34
- Dividend Yield 0.00 %
- ROCE -13.9 %
- ROE -25.7 %
- Face Value ₹ 1.00
Pros
- Company has reduced debt.
- Debtor days have improved from 103 to 58.0 days.
- Company's working capital requirements have reduced from 118 days to 20.4 days
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -34.7% over past five years.
- Company has a low return on equity of -49.0% over last 3 years.
- Contingent liabilities of Rs.97.9 Cr.
- Promoter holding has decreased over last 3 years: -13.5%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Miscellaneous Industry: Miscellaneous
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
704 | 832 | 816 | 730 | 1,030 | 1,345 | 1,587 | 2,039 | 2,213 | 774 | 655 | 189 | |
559 | 670 | 668 | 581 | 817 | 1,082 | 1,281 | 1,655 | 2,044 | 847 | 648 | 208 | |
Operating Profit | 145 | 161 | 147 | 149 | 213 | 262 | 307 | 384 | 169 | -73 | 7 | -19 |
OPM % | 21% | 19% | 18% | 20% | 21% | 20% | 19% | 19% | 8% | -9% | 1% | -10% |
15 | 7 | 6 | 8 | 21 | 13 | 6 | 11 | 26 | -211 | -677 | -55 | |
Interest | 18 | 14 | 14 | 13 | 15 | 23 | 21 | 25 | 41 | 37 | 29 | 7 |
Depreciation | 27 | 46 | 77 | 60 | 74 | 87 | 104 | 154 | 167 | 115 | 80 | 17 |
Profit before tax | 115 | 107 | 63 | 85 | 145 | 165 | 188 | 216 | -13 | -437 | -779 | -99 |
Tax % | 18% | 17% | 2% | 6% | 14% | 11% | 15% | 17% | 15% | -3% | -0% | -2% |
Net Profit | 94 | 89 | 62 | 80 | 125 | 146 | 160 | 178 | -11 | -450 | -782 | -100 |
EPS in Rs | 6.99 | 6.49 | 4.74 | 5.71 | 9.78 | 10.74 | 10.85 | 11.99 | -0.84 | -30.56 | -52.88 | -6.78 |
Dividend Payout % | 14% | 15% | 21% | 17% | 10% | 9% | 15% | 8% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | -14% |
5 Years: | -35% |
3 Years: | -56% |
TTM: | -71% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 95% |
Stock Price CAGR | |
---|---|
10 Years: | -5% |
5 Years: | -40% |
3 Years: | -33% |
1 Year: | -25% |
Return on Equity | |
---|---|
10 Years: | -4% |
5 Years: | -17% |
3 Years: | -49% |
Last Year: | -26% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
12 | 12 | 12 | 12 | 12 | 13 | 15 | 15 | 15 | 15 | 15 | 15 | |
Reserves | 330 | 408 | 458 | 512 | 619 | 898 | 1,314 | 1,504 | 1,561 | 1,110 | 166 | 94 |
193 | 196 | 207 | 209 | 336 | 237 | 323 | 474 | 553 | 514 | 59 | 46 | |
206 | 220 | 185 | 189 | 246 | 221 | 189 | 339 | 336 | 187 | 984 | 69 | |
Total Liabilities | 741 | 837 | 862 | 922 | 1,214 | 1,369 | 1,840 | 2,331 | 2,465 | 1,826 | 1,223 | 224 |
339 | 368 | 384 | 359 | 543 | 554 | 589 | 1,091 | 1,234 | 934 | 101 | 74 | |
CWIP | 1 | 3 | 2 | 17 | 3 | 21 | 42 | 41 | 1 | 0 | 3 | 10 |
Investments | 50 | 50 | 50 | 6 | 21 | 10 | 59 | 10 | 18 | 7 | 0 | 0 |
351 | 415 | 426 | 541 | 647 | 785 | 1,150 | 1,188 | 1,213 | 885 | 1,119 | 140 | |
Total Assets | 741 | 837 | 862 | 922 | 1,214 | 1,369 | 1,840 | 2,331 | 2,465 | 1,826 | 1,223 | 224 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
115 | 117 | 100 | 74 | 151 | 56 | 121 | 104 | 211 | 135 | 30 | ||
-81 | -70 | -91 | -14 | -292 | -130 | -179 | -474 | -233 | -57 | 15 | ||
-21 | -31 | -7 | -11 | 111 | 56 | 302 | 100 | 21 | -84 | -55 | ||
Net Cash Flow | 13 | 16 | 2 | 49 | -30 | -18 | 243 | -270 | -2 | -6 | -10 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 82 | 99 | 100 | 120 | 107 | 118 | 108 | 94 | 116 | 205 | 45 | 58 |
Inventory Days | 3 | |||||||||||
Days Payable | 104 | |||||||||||
Cash Conversion Cycle | 82 | 99 | 100 | 120 | 107 | 118 | 108 | 94 | 116 | 205 | 45 | -42 |
Working Capital Days | 55 | 71 | 83 | 121 | 107 | 136 | 143 | 142 | 137 | 289 | 45 | 20 |
ROCE % | 26% | 21% | 12% | 14% | 17% | 17% | 15% | 13% | 1% | -9% | -6% | -14% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
2d - Extract of the Consolidated Audited Financial Results for the quarter and year ended March 31, 2023, published in newspapers, namely, Makkal Kural (Tamil) and Financial …
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
30 May - Secretarial Compliance Report of the Company for the year ended March 31, 2023.
- Disclosure Of Related Party Transactions Pursuant To Regulation 23(9) Of SEBI (LODR) Regulations, 2015 ('LODR') 29 May
- Outcome Of The Board Meeting Held On Monday, May 29, 2023 29 May
- Board Meeting Outcome for Outcome Of The Board Meeting Held On Monday, May 29, 2023 29 May
Annual reports
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2010
from nse
Concalls
-
Aug 2021TranscriptPPT
-
Jun 2021TranscriptPPT
-
Feb 2021TranscriptPPT
-
Dec 2020TranscriptPPT
-
Sep 2020TranscriptPPT
-
Oct 2019TranscriptPPT
-
Aug 2019TranscriptPPT
-
May 2019TranscriptPPT
-
Mar 2019TranscriptPPT
-
Feb 2019TranscriptPPT
-
Feb 2019TranscriptPPT
-
Aug 2018TranscriptPPT
-
May 2018TranscriptPPT
-
Feb 2018TranscriptPPT
-
Nov 2017TranscriptPPT
-
Nov 2017TranscriptPPT
-
Aug 2017TranscriptPPT
-
May 2017TranscriptPPT
-
Jan 2017TranscriptPPT
-
Dec 2016TranscriptPPT
-
Oct 2016TranscriptPPT
-
Feb 2016TranscriptNotesPPT
Services Offering
Life Sciences: The Company offers clients a unique combination of full-service Clinical Research, Generics Development, Data Sciences, Regulatory Affairs, and Pharmacovigilance/Safety services backed by distinctive technology expertise. [1]